MORPHOTYPES' CHANGE OF TESIOGRAMMS OF PATIENTS WITH LOCALLY-ADVANCED BREAST CANCER ON THE BACKGROUND OF NEOADYAVANT CHEMOTHERAPY
Abstract
Study of blood plasma tesiogramms was performed in 51 patients with locally advanced breast cancer who received three regimens of neoadjuvant chemotherapy. The control sample consisted of 10 practically healthy women. All patients are divided into 3 groups - 2 studied, one - control. In the control group, patients received 4 courses of neoadjuvant chemotherapy according to the AC-protocol (doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2). The study group 1st received 4 courses of chemotherapy according to the protocol AC+Arglabin (Arglabin 370 mg/m2 7 days), the study group 2nd - 4 courses of Arglabin. Three morphotypes of tesiogramms in patients with breast cancer before treatment have been described. There were revealed specific signs of a change in the tesiographic picture of blood in patients who received different regimens of chemotherapy. It has been shown that arglabin, both in mono regimen and in combination with AC, promotes a rise in the blood of hydrophobic components, which may be indirectly indicative of increased cytolysis of tumor cells in the body, which correlates with the clinical efficacy of chemotherapy.
About the Authors
S. S. Zhumakayeva
Karaganda state medical university
Kazakhstan
Kazakhstan
L. Ye. Muravlyova
Karaganda state medical university
Kazakhstan
Kazakhstan
O. A. Ponamaryova
Karaganda state medical university
Kazakhstan
Kazakhstan
V. B. Sirota
Karaganda state medical university
Kazakhstan
Kazakhstan
References
1. Адекенов С. М. Перспективы производства и применения нового оригинального препарата «Арглабин» //Матер. междунар. науч.-практ. конф. «Клинические аспекты применения противоопухолевого препарата Арглабин». - Караганда, 2002. - С. 12-24.
2. Мезенцева М. В. Иммунологическая эффективность арглабина в терапии рака молочной железы /М. В. Мезенцева, В. Э. Щербенко, Ф. И. Ершов //Рос. биотерапевт. журн. -2005. - №2. - С. 64-67.
3. Нургазиев Р. И. Показатели онкологической службы Республики Казахстан за 2014 год (статистические материалы) /Р. И. Нургазиев, Г. Д. Сейтказина, Д. М. Байпеисов. - Алматы, 2015. - 138 с.
4. Шабалин В. Н. Морфологии биологических жидкостей человека /В. Н. Шабалин, С.Н. Шатохина. - М.: Хризостом, 2001. - 304 с.
5. Шайкенов Т. Е. Влияние арглабина на индукцию апоптоза опухолевых клеток и ингибирование фарнезилтрансферазы как возможный механизм действия /Т. Е. Шайкенов, Ф. Л. Бейкер, Л. Вульфинбаргер //Рос. биотерапевт. журн. - 2005. - №2. - С. 18-23.
6. Шайкенов Т. Е. Об избирательном действии препарата Арглабин на трансформированные клетки in vitro /Т. Е Шайкенов., К. Д. Рахимов, С. М. Адекенов //Вестник АН РК. -1996. - №6. - С. 55-59.
7. Bear H. D. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 /H. D. Bear, S. Anderson, R. E. Smith //J. Clin. Oncol. - 2006. -V. 24(13). - Рp. 2019-2027.
8. Chollet P. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer /P. Chollet, S. Amat, H. Cure //Brit. J. Cancer. - 2002. -V. 86. - P. 1041-1046.
9. Lena M. High efficacy of paclitaxel and doxorubicin as fist line therapy in advanced breast cancer /M. Lena, A. Zatorre //Chemother. - 2000. - №4(12). - P. 367-373.
10. Mieog J. S. Neoadjuvant chemotherapy for operable breast cancer /J. S. Mieog, J. A.van der Hage, C. J. van de Velde //Br. J. Surg. -2007. - V. 94. - Р. 1189-1200.
11. Shaikenov T. E. Arglabin inhibits farnesylation of ras protein and cell proliferation /T. E. Shaikenov, S. M. Adekenov, F. L. Baker et al. // Proceeding of the AACR, 90th Annual meeting. -Philodelfia, 1999: Abstract 2474.
12. Van de Wiel M. Neoadjuvant systemic therapy in breast cancer: Challenges and uncertainties //Eur. J. Obstet. Gynecol. Reprod. Biol. -2016. - V. 210. - Р. 144-156.
13. Zardavas D. Neoadjuvant therapy for breast cancer /D. Zardavas, M. Piccart //Annu. Rev. Med. - 2015. - V. 66. - Р. 31-48.
Review
For citations:
Zhumakayeva S.S., Muravlyova L.Ye., Ponamaryova O.A., Sirota V.B. MORPHOTYPES' CHANGE OF TESIOGRAMMS OF PATIENTS WITH LOCALLY-ADVANCED BREAST CANCER ON THE BACKGROUND OF NEOADYAVANT CHEMOTHERAPY. Medicine and ecology. 2018;(1):128-134. (In Russ.)
Views: 181
Email this article 